Creighton to Explore Usage of Adult Stem Cells to Improve Angioplasty Results A Creighton University School of Medicine researcher has received a $3.3 million, five-year grant from the National Institutes of Health to study what role adult stem cells might play in repairing damaged coronary arteries. [Creighton University] Press Release BioTime Licenses Technology for Key Regulatory Gene Underlying Cancer and Stem Cell Reprogramming from The Wistar Institute BioTime, Inc. announced that it has obtained an exclusive license from The Wistar Institute in Philadelphia, PA for technology related to a gene designated as SP100. Wistar Institute researchers have demonstrated pivotal roles for this gene in both cancer and stem cell biology. [BioTime, Inc.] Press Release Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase II Trial for Acute Myocardial Infarction Amorcyte, LLC, a NeoStem, Inc. company announced the enrollment of the first patient in the Amorcyte PreSERVE Phase II trial for acute myocardial infarction. The study is a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of infarct-related artery infusion of AMR-001, an autologous bone marrow derived cell therapy enriched for CD34+ cells. [NeoStem, Inc.] Press Release Vet-Stem Announces Milestone of 8,000 Animals Treated with Vet-Stem Cell Therapy Vet-Stem Inc., announced that over 8,000 animals have now been treated with Vet-Stem cell therapy. [Vet-Stem Inc.] Press Release Charter Medical Receives CE Mark Clearance for Next Generation Cell Freeze® Cryogenic Stem Cell Storage Containers Charter Medical, Ltd., a Lydall subsidiary, announced that it received CE Mark approval on its next generation Cell Freeze® Cryogenic Storage Containers for Hematopoietic Progenitor Cells. [Lydall, Inc.] Press Release World-Renowned Cell-Therapy Researcher, Doris Taylor, PhD, Joins Texas Heart Institute at St. Luke’s Episcopal Hospital Officials at the Texas Heart Institute (THI) at St. Luke’s Episcopal Hospital announced that Doris Taylor, PhD, FAHA, FACC, one of the world’s leading cell therapy and cardiac regeneration scientists, will join THI beginning March 1, 2012. [Texas Heart Institute] Press Release TAP Biosystems’ Project to Manufacture 3D Tissue Equivalents – Develops Potential Cell Therapy for Corneal Surface Disease TAP Biosystems is pleased to announce that its Technology Strategy Board funded project with UCL scientists has made a significant advance towards developing a tissue-engineered, biomimetic cornea as a therapy. [TAP Biosystems] Press Release Can Gene Therapy Be Used to Prevent Vein Graft Disease? A grant of over £100,000 to investigate gene therapy in vein grafts that are used in heart bypass surgery has been awarded to Gavin Murphy, Reader in Cardiac Surgery in the School of Clinical Sciences at the University of Bristol from national heart charity, Heart Research UK. [University of Bristol] Press Release French Institute Prepares for Gene-Therapy Push Scientific director Fulvio Mavilio has a mandate to sharpen the research profile of Genethon. One of his main strategies is to create international clinical networks for gene therapy around Genethon. [NatureNews] Press Release Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Second Generation Lipid Nanoparticles (LNP) for Systemic Delivery of RNAi Therapeutics Alnylam Pharmaceuticals, Inc. announced that the USPTO has issued a Notice of Allowance for patent application number 12/813,448, covering the company’s proprietary second generation LNP platform, including the “MC3” lipid. [Alnylam Pharmaceuticals, Inc.] Press Release
Prosensa Raises €23 Million in New Equity Financing Led by New Enterprise Associates The fundraising will enable Prosensa to advance its portfolio of RNA-modulating therapeutics for the treatment of rare diseases, including Duchenne muscular dystrophy, Myotonic Dystrophy and Huntington’s disease. [Prosensa] Press Release World-Class Scientists Chosen for HHMI’s First International Early Career Award Top biomedical scientists from 12 countries will receive an important boost at a critical time in their careers from the Howard Hughes Medical Institute’s (HHMI’s) inaugural International Early Career Scientist awards. [Howard Hughes Medical Institute] Press Release |